Search the Newsreel

Avalo Therapeutics (AVTX) CSO Riley sells 2,655 shares at about $19.59

Avalo Therapeutics' Chief Strategy Officer, Jennifer Riley, sold 2,655 shares of common stock on August 11, 2026, at a weighted average price of $19.5903 per share. The transactions occurred within a price range of $19.54 to $19.65. Following this sale, Riley directly holds 37,041 …

Avalo Therapeutics (AVTX) CMO Mittie Doyle exercises options and sells 679 shares

Avalo Therapeutics (AVTX) Chief Medical Officer Mittie Doyle exercised options for 679 shares at $8.04 per share and subsequently sold the same number of shares at $20.00 per share on August 10, 2026. These transactions were executed under a pre-established Rule 10b5-1 trading plan. …

Avantium N.V.: Fundamentele analyse en financiële beoordelingen | 0RNP | NL0015002IE0

Avalo Therapeutics, Inc. $AVTX Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in Avalo Therapeutics (NASDAQ:AVTX) by 556.4% in the first quarter, now owning 120,114 shares valued at $1.79 million. Despite this institutional interest, Avalo Therapeutics faces challenging financial prospects with missed earnings expectations and projected future losses. Wall …

Equities Analysts Issue Forecasts for AVTX Q3 Earnings

Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?

Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX)

Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating on Avalo Therapeutics (AVTX) with a price target of $35.00. This comes despite the company reporting a wider GAAP net loss of $36.36 million in its latest quarterly earnings compared to the previous …

Avalo Therapeutics (NASDAQ:AVTX) Rating Lowered to "Sell" at Wall Street Zen

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $45.80, significantly above its current trading price of $18.70. Despite strong institutional ownership at 87.06% and recent buying activity, the company reported an adjusted …

AVTX Maintains Buy Rating by Guggenheim -- Price Target Lowered to $48

Guggenheim maintained a Buy rating for Avalo Therapeutics (AVTX) but lowered its price target from $50.00 to $48.00, reflecting a cautious outlook due to clinical development challenges. The stock is considered significantly overvalued with a GF Value™ of $0.03 against a current price of …

Avalo Therapeutics Inc (AVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

FMR LLC discloses 10.8% Avalo Therapeutics (AVTX) holding in Schedule 13G/A

FMR LLC has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 5,737,966 shares of Avalo Therapeutics, Inc. (AVTX), which represents 10.8% of the company's common stock. The filing indicates FMR LLC holds sole dispositive power over all these shares and sole voting …

State Street Corporation (NYSE: AVTX custodian) discloses 5.5% Avalo stake

State Street Corporation has disclosed a 5.5% beneficial ownership stake in Avalo Therapeutics, Inc. (AVTX) through a Schedule 13G filing. The investment firm reported owning 2,889,287 shares, with shared voting power over 2,837,724 shares and shared dispositive power over all 2,889,287 shares. Subsidiaries involved …

Avalo Therapeutics Releases Q2 2026 Financial Results

Avalo Therapeutics reported narrower losses for Q2 2026, with a net loss of $36.4M and a loss of $0.83 per share, significantly improving from the prior year. The clinical-stage biotechnology company is developing IL-1ß-based treatments and maintains a positive outlook from Wall Street analysts. …

Avalo Therapeutics, Inc. Stock 12‑Month Price Target Raised to $45.33, Implies 141% Upside

Avalo Therapeutics, Inc.'s stock price target has been increased to $45.33 from $44.69 by 12 analysts, implying a potential upside of 141% from its August 5th closing price. The consensus rating from 14 covering analysts remains a "Buy," with no "Holds" or "Sells."

Price-Driven Insight from (AVTX) for Rule-Based Strategy

This article provides a price-driven analysis for Avalo Therapeutics Inc. (NASDAQ: AVTX), highlighting weak near-term sentiment but potential long-term strength. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, along with a multi-timeframe signal analysis. The …

Avalo Therapeutics, Inc. 2026: Revenue ($36.94M), Net income ($36.36M), EPS ($0.83) — 10-Q Summary

Avalo Therapeutics, Inc. reported a comprehensive loss of ($36.94M) and a net loss of ($36.36M) for the quarter ended 2026, with diluted loss per share at ($0.83). The company achieved positive Phase 2 results for abdakibart in hidradenitis suppurativa and completed a $405M equity …

Avalo Therapeutics (NASDAQ:AVTX) Issues Quarterly Earnings Results, Misses Expectations By $0.27 EPS

Avalo Therapeutics Inc expected to post a loss of 58 cents a share - Earnings Preview

Avalo Therapeutics Inc is projected to report a loss of 58 cents per share in its upcoming earnings release. This forecast is based on an earnings preview from Refinitiv. The full article content is behind a paywall, requiring a TradingView subscription for unlimited access.

DV Trading LLC Invests $5.38 Million in Avalo Therapeutics, Inc. $AVTX

Avalo Therapeutics Inc Revenue Breakdown – DUS:C6K0

Avalo Therapeutics Inc (DUS:C6K0) generated 50.23K EUR last year, a significant decrease from 426.00K EUR the previous year. The pharmaceutical segment was its top-performing segment, contributing all of the company's revenue, and the United States was the primary source of this revenue.

Avalo Therapeutics Inc (AVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Avalo Therapeutics Inc (AVTX), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of the analysis, AVTX has a price momentum score of 3.95 and is trading between a …

Avalo Therapeutics earnings up next: Pipeline progress in focus By Investing.com

Avalo Therapeutics is set to report Q2 earnings, with investors keenly focused on the progress of its hidradenitis suppurativa treatment, abdakibart, towards pivotal trials. Despite an expected loss, the company's stock has significantly risen, and analysts maintain a strong buy rating with substantial upside …

Avalo Therapeutics, Inc. SEC Filing (Jul 29, 2026)

This article reports on Avalo Therapeutics, Inc.'s SEC filing, specifically an EFFECT filing dated July 29, 2026. The filing indicates a "Neutral" impact and sentiment. It details that the filing is a Notice of Effectiveness for Form S-3, with an effectiveness date of July …

Avalo Therapeutics (AVTX) Expected to Post Earnings on Thursday

Avalo Therapeutics (AVTX) CMO sells 1,000 shares after option exercise

Avalo Therapeutics' Chief Medical Officer, Mittie Doyle, exercised 1,000 stock options at $12.65 per share and subsequently sold all 1,000 shares at $20.00 each on July 27, 2026. This transaction, executed under a Rule 10b5-1 trading plan, resulted in an approximate pre-tax spread of …

Avalo Therapeutics Inc (AVTX) Institutional Confidence

Avalo Therapeutics Inc (AVTX) has an institutional shareholding score of 5.00, placing it 132nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 60.06%, a 20.42% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 3.72% of …

Exome Asset Management LLC Makes New $2.38 Million Investment in Avalo Therapeutics, Inc. $AVTX

Avalo Therapeutics Inc (AVTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Avalo Therapeutics Inc (AVTX) stock information, focusing on its dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years and lists several merger-related stock splits that occurred …

BlackRock Inc. (AVTX) discloses 6.5% Avalo Therapeutics stake on Schedule 13G

BlackRock, Inc. has disclosed a passive ownership stake of 6.5% in Avalo Therapeutics Inc. common stock, as reported in a Schedule 13G filing. This amounts to 3,415,731 beneficially owned shares, with BlackRock retaining sole voting power over 3,371,733 shares and sole dispositive power over …

Avalo Therapeutics Inc (AVTX) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Avalo Therapeutics Inc (AVTX), noting its current valuation score of 6.96, which ranks 268 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -3.50, which is significantly below …

Orbimed Advisors LLC Has $7.09 Million Stock Position in Avalo Therapeutics, Inc. $AVTX

Avalo Therapeutics Inc Revenue Breakdown – TRADEGATE:C6K0

Avalo Therapeutics Inc (C6K0) generated 50.23K EUR in revenue last year, primarily from its Pharmaceutical segment, which is a decrease from 426.00K EUR the previous year. All reported revenue for the company came from the United States. The company's financial performance shows a significant …